Molecular imaging developer Avid Radiopharmaceuticals of Philadelphia has released results of the company's first clinical study of a new radiopharmaceutical designed to provide PET imaging of Alzheimer's disease.
Avid's AV-1 agent (18F-AV-1/ZK) is designed to image the beta amyloid plaques that accumulate abnormally in Alzheimer's patients. In the study, researchers were able to determine that AV-1 distinguishes patients with Alzheimer's disease from healthy controls, according to Dr. Christopher Rowe from Austin Hospital of Melbourne. Rowe presented the results at the eighth annual International Conference on AD/PD in Salzburg, Austria.
Rowe said that AV-1 PET scans showed high levels of signal in Alzheimer's patients, particularly in areas of the brain known to contain amyloid plaques. In contrast, there was no retention of AV-1 in the cerebellar cortex, an area where amyloid plaques do not accumulate, according to the company.
By AuntMinnie.com staff writers
March 23, 2007
Related Reading
Schering, Avid partner on Alzheimer's agents, July 17, 2007
Avid gets funding for new radiotracer, January 25, 2005
Copyright © 2007 AuntMinnie.com
